APOA1

(redirected from apo-AI)

APOA1

A gene on chromosome 11q23-q24 that encodes apolipoprotein A1, the main protein component of high-density lipoprotein (HDL) in plasma, which promotes cholesterol efflux from tissues to the liver for excretion and is a cofactor for lecithin cholesterolacyltransferase (LCAT), which is responsible for forming most plasma cholesteryl esters.
 
Molecular pathology
APOA1 mutations cause HDL deficiency (e.g., Tangier disease and systemic non-neuropathic amyloidosis).
References in periodicals archive ?
SUSTAIN also successfully met secondary endpoints, showed increases in levels of Apo-AI (p=0.
The primary purpose of the SUSTAIN trial was to measure changes in HDL, Apo-AI and other lipid parameters compared with placebo, while also assessing safety over an extended treatment period in the patient population with the largest response to RVX-208 in the phase 2 ASSERT trial.
Later, as an NIH postdoc, he focused on such topics as the compositional and functional properties of HDL in patients with ischemic heart disease, and the characterization and function of new Apo-AI mimetic peptides potentially to be used as HDL-C raising compounds.